Detalhe da pesquisa
1.
Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood During Maintenance Therapy in Multiple Myeloma.
Blood
; 2024 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38713888
2.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(2): 139-150, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36642080
3.
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
Br J Haematol
; 203(5): 792-802, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37691005
4.
Measurable residual disease in peripheral blood in myeloma: dream or reality.
Curr Opin Oncol
; 35(6): 574-580, 2023 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37621165
5.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist
; 27(7): e589-e596, 2022 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35462406
6.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood
; 136(22): 2513-2523, 2020 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32735641
7.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Br J Haematol
; 186(4): 549-560, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31124580
8.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 372(2): 142-52, 2015 Jan 08.
Artigo
Inglês
| MEDLINE | ID: mdl-25482145
9.
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Blood
; 127(22): 2693-700, 2016 06 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27009059
10.
Initial genome sequencing and analysis of multiple myeloma.
Nature
; 471(7339): 467-72, 2011 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-21430775
11.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer
; 122(21): 3327-3335, 2016 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27433944
12.
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Blood
; 124(7): 1038-46, 2014 Aug 14.
Artigo
Inglês
| MEDLINE | ID: mdl-24920586
13.
Clinician attitudes and practices toward measurable residual disease in multiple myeloma.
Br J Haematol
; 190(3): 470-472, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32506429
14.
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Br J Haematol
; 170(1): 66-79, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25824111
15.
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Blood
; 120(9): 1801-9, 2012 Aug 30.
Artigo
Inglês
| MEDLINE | ID: mdl-22665938
16.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Blood
; 120(14): 2817-25, 2012 Oct 04.
Artigo
Inglês
| MEDLINE | ID: mdl-22833546
17.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Artigo
Inglês
| MEDLINE | ID: mdl-22555973
18.
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood
; 118(3): 535-43, 2011 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-21596852
19.
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Blood Adv
; 7(19): 5703-5712, 2023 10 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763537
20.
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Br J Haematol
; 158(4): 472-80, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22640031